Objective: The purpose of this study was to determine the incidence and significance of aneurysm enlargement, with or without treatment, in relation to the primary end points of rupture, surgical conversion, aneurysm-related death, and survival following endovascular repair. Method: Aneurysm (AAA) size changes and clinical outcome of all patients treated from 1997 through 1998 during the Phase II AneuRx multicenter clinical trial of endovascular AAA repair were reviewed. Aneurysm dimensions and the presence or absence of endoleak were determined by an independent core laboratory, with enlargement or shrinkage defined as a diameter change of 5 mm or more compared with baseline. Results: Among 383 patients (89% men, 11% women, age 73 ؎ 9 years), with a mean device implant time of 36 ؎ 11 months (median ‫؍‬ 39 months), aneurysm diameter decreased from 5.7 ؎ 1.0 at baseline to 5.2 ؎ 1.0 at 3 years (P ‫؍‬ .0001). A total of 46 patients (12%) experienced AAA enlargement, 199 patients (52%) had no change in AAA diameter, and 138 patients (36%) had a decrease in AAA diameter of 5 mm or more. Significant risk factors for enlargement included age (enlargement patients were 4 years older on average than patients with aneurysms that decreased in size; P ‫؍‬ .002) and the presence of an endoleak (P < .001). Among patients with endoleak at any time, 17% had aneurysm enlargement, whereas only 2% of patients without endoleak had aneurysm enlargement (P < .001). Patients with enlargement were more likely to undergo secondary endovascular procedures and surgical conversions (P < .001). Twenty patients (43%) with enlargement underwent treatment, and 26 patients were untreated. There were two deaths following elective surgical conversion and one death in a patient with untreated enlargement and a type I endoleak. Three aneurysms ruptured: one with enlargement, one with no change, and one with a decrease in aneurysm size; all three aneurysms were larger than 6.5 cm. Kaplan-Meier analysis showed that freedom from rupture at 3 years was 98% with enlargement, 99% with no change, and 99% with decrease in AAA size (log-rank test, not significant). Freedom from AAA death at 3 years was 93% in patients with enlargement, 99% in no increase, and 99% in decrease (P ‫؍‬ .005). Survival at 3 years was 86% with increase, 82% with no change, and 93% with decrease (P ‫؍‬ .02). Aortic aneurysms enlarge over time, with an increasing risk of rupture directly related to aneurysm size.
Aortic aneurysms enlarge over time, with an increasing risk of rupture directly related to aneurysm size. [1] [2] [3] [4] Although the annual risk of rupture of small aneurysms 4 to 5 cm in diameter is relatively low (0.5%-5%), the annual risk of rupture of 5-to 6-cm aneurysms is 3%-15%. 5 If aneurysms are untreated, the 1-year risk of rupture of 5.5-to 6.4-cm aneurysms is 10%, of 6.5-to 7.0-cm aneurysms is 19%, and of aneurysms greater than 7.0 cm is 33%. 6 Although the relationship between absolute aneurysm size and rupture is well known, the significance of aneurysm enlargement is less clear. [5] [6] [7] [8] Evidence of recent or rapid aneurysm enlargement is thought to presage aneurysm rupture and is commonly used as an indication for surgical 9, 10 or endovascular aneurysm treatment. 11 However, enlargement alone, independent of aneurysm size, has not been found to predict the risk of rupture in prospective clinical trials 10 or surveillance studies of nonsurgical patients.
of rupture following endovascular repair independent of other factors that may be important, such as fixation and type I endoleak. Ruptures have been reported with all endovascular devices and are often specifically related to the endovascular device or its fixation to the aortic neck or iliac arteries. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Ruptures have been found in patients with no endoleaks and decreasing aneurysm size, as well as in patients with endoleaks and increasing aneurysm size. 13, 22 Independent core laboratory evaluation of endoleaks in the AneuRx clinical trial revealed that the presence of an endoleak following stent-graft repair was not a significant predictor of primary or secondary outcome measures. 23 Although the presence of an endoleak at 1 month was associated with an increased likelihood of aneurysm enlargement, it was not associated with aneurysm rupture following the procedure. 23 It was unclear whether aneurysm enlargement with longer patient follow up would become a meaningful predictor of risk of rupture following endovascular repair.
The purpose of this investigation was to determine the incidence and significance of aneurysm enlargement following endovascular repair and to relate this finding to the primary objective of aneurysm treatment, namely, preventing aneurysm rupture. We used independent core laboratory documentation of changes in aneurysm size with a mean follow-up time of 36 months after endovascular repair.
METHOD
All patients treated with the AneuRx stent-graft system (Medtronic AVE, Santa Rosa, Calif) during the phase II clinical trial of endovascular aneurysm repair from April 1997 through September 1998 were reviewed. Thirteen clinical sites (see Appendix, online only) enrolled and treated 424 patients who met the inclusion criteria of the trial as well as 46 patients who did not meet the inclusion criteria and were treated on an "emergency use" basis, for a total of 470 patients. Details of the study design and patient eligibility have previously been published; 24, 25 selection criteria included an abdominal aortic aneurysm (AAA) with an infrarenal neck length of at least 10 mm and a neck diameter between 18 and 26 mm with a maximum distal iliac diameter of 15 mm. Patients were evaluated with preprocedure and postprocedure contrast computed tomography (CT) scans with scheduled follow-up imaging at 1, 6, and 12 months and at yearly intervals thereafter. Additional interval CT scans at more frequent intervals were obtained as clinically indicated. An independent core laboratory, which had no involvement with any of the clinical investigation sites and was blinded from patient identification and clinical information, interpreted CT scans and abdominal radiographs submitted by the clinical sites.
The core laboratory reported aortic aneurysm diameter at each time point as the largest wall-to-wall diameter of the aneurysm on cross-sectional contrast CT scans. The initial postprocedure CT scan (predischarge CT, obtained within 4 days in 95% of patients), 23 was used as the baseline for determination of subsequent changes in aneurysm diameter. An increase or decrease of maximum aneurysm diameter of 5 mm or more, compared with the baseline scan at any follow-up time point, was considered to be a significant change in aneurysm size. Patients were assigned to the increase or decrease group the first time their aneurysm size met the 5-mm threshold of change. Patients remained in that group regardless of subsequent changes in aneurysm size due to therapy or other reasons. The core laboratory also reported on the integrity of the stent graft, the presence or absence of an endoleak, and the dimensions of the infrarenal aortic neck and iliac arteries. Clinical information on each patient was reported by each of the 13 clinical sites to a centralized data registry and was not available to the core laboratory. Primary clinical end points included aneurysm rupture (intraoperative, perioperative, and postoperative ruptures), aneurysm-related death (any death within 30 days of a primary or secondary procedure related to aneurysm rupture, thrombosis, or device failure), surgical conversion (perioperative and late open surgical aneurysm repair), and overall survival (death from any cause). Secondary procedures for any cause, including aneurysm enlargement, endoleak, stent-graft migration, and graft limb thrombosis, were recorded. All patients were reviewed, with a clinical follow-up data freeze as of August 2001. Patients who had both a postprocedure CT scan and at least one follow-up CT scan, which were evaluated and reported by the core laboratory so that changes in aneurysm diameter could be determined, are the subject of this report. A total of 383 patients met these criteria. Patients were divided into three groups on the basis of aneurysm diameter change from baseline during the follow-up period: increase in diameter of 5 mm or more, no change in diameter at any time, or decrease in diameter of 5 mm or more.
Results were expressed as the mean and median Ϯ standard deviation. Differences among the three patient groups for all end points were determined by using analysis of variance for continuous data and 2 and Fisher exact tests for categorical data. Time-dependent data were analyzed by using the Kaplan-Meier method and compared by using the log-rank test. Differences with P Ͻ .05 were considered to be significant.
RESULTS
Patient population. Among the population of 470 patients treated during the phase II AneuRx trial, 383 patients had two or more postprocedure core laboratory measurements of maximum aortic aneurysm diameter so that changes in aneurysm size could be determined. Eightyseven patients did not meet the inclusion criteria for this study for the following reasons (listed hierarchically, with each patient counted once): device not implanted, 9 patients; death within 30 days, 7 patients; surgical conversion, 3 patients; no core laboratory report of a postprocedure CT scan, 43 patients; no core laboratory report of a follow-up CT scan, 25 patients.
Mean preoperative aortic aneurysm diameter among the 383 patients was 5.7 Ϯ 1.0 cm (median, 5.5 Ϯ 1.0 cm), and mean implant duration was 36 Ϯ 11 months (median, 39 months; range, 2-52 months). The mean number of postprocedure CT scans per patient was 3.4 Ϯ 1.5 (range, 1-11 scans per patient). The number of CT scans with core laboratory data at each time point along with mean and median aneurysm diameters is shown in Table I . Mean aneurysm diameter for the entire group decreased over the 3-year observation period to a mean diameter of 5.2 Ϯ 1.0 cm (median, 5.0 Ϯ 1.0 cm) at 3 years (P ϭ .001 compared with baseline; Fig) . Endoleak rate at 1 year was 20%, at 2 years was 21%, and at 3 years was 22%, with an endoleak distribution of approximately 12% type I, 72% type II, 10% type III, and 6% type IV in each year.
Aneurysm size changes. A total of 46 patients (12%) experienced aneurysm enlargement, with an increase in aneurysm size of 5 mm or more at some time during the follow-up period; 199 patients (52%) had no change in aneurysm size; and 138 patients (36%) had a decrease in aneurysm size of 5 mm or more at some time during the follow-up period (Table II) . There were no significant differences among the three patient groups with regard to preoperative risk factors, with the exception that patients with aneurysm enlargement were 4 years older on average than patients with aneurysms that decreased in size (P ϭ .002). Changes in aneurysm size are shown in Table III . There were no significant differences in aneurysm diameter at baseline among patients with enlargement, and no change or decrease in aneurysm size. Enlargement patients had a mean increase in aneurysm size of 0.9 cm (range, 0.5-3.0 cm), whereas patients with shrinking aneurysms had a mean decrease in size of 1.0 cm (range, 0.5-2.6 cm). There was no difference in the mean rate of change in aneurysm size among patients with enlarging aneurysms (ϩ0.31 mm per month) and patients with shrinking aneurysms (Ϫ0.31 mm per month).
Endoleak and migration. Endoleaks were reported by the core laboratory at some time during the follow-up period in 54% of patients. Among patients with endoleak at any time, 17% had aneurysm enlargement, whereas only 2% of patients without endoleak had aneurysm enlargement (P Ͻ .001). Patients with aneurysm enlargement were more likely to have had an endoleak at some time following device implantation (38 of 46 patients, 83%) than patients with no change (113 of 196 patients, 58%) or patients with a decrease in aneurysm size (54 of 136 patients, 40%; P Ͻ .0001. At 1 year, 56% of patients with enlargement had endoleaks, 23% of patients with no change in aneurysm size had endoleaks, and 6% of patients with decreasing aneurysm size had endoleaks (P Ͻ .0001; Table IV ). This distribution remained unchanged at the end of 3 years. The majority of endoleaks (72%) were type II endoleaks, and there was no difference in distribution of type I and type II endoleaks among the three patient groups. Migration was noted by the core laboratory in 24 of 383 patients (6%), with no significant difference in migration rate among the three patient groups (Table IV) .
Secondary procedures. Secondary procedures were performed in 70 of 383 patients (18%). Patients with aneurysm enlargement were more likely to undergo a secondary procedure (21 of 46 patients, 46%) than patients with no change (33 of 199 patients, 17%) or decreasing aneurysm size (16 of 138 patients, 12%; P ϭ .0001). Secondary procedures in enlargement patients included placement of proximal or distal stent-graft extender modules (10 patients), coil embolization for endoleaks (five patients), treatment of graft-limb occlusions with femoralfemoral bypass (four patients), and angioplasty and stenting for iliac stenosis (two patients). Eight of the enlargement patients who had secondary procedures had documented aneurysm enlargement before the secondary procedure, and seven had documented enlargement after the secondary treatment. Four enlargement patients who had secondary treatments subsequently underwent surgical conversion. Kaplan-Meier estimates for freedom from secondary procedures at 3 years were 62% for patients with aneurysm enlargement, 83% for patients with no change, and 88% for patients with decreasing aneurysm size (log-rank test, P Ͻ .0001).
Surgical conversion. Open surgical aneurysm repair was performed in 18 of 383 patients (4.7%). Of these, 9 surgical conversions were performed in patients with enlargement, 7 were performed in patients with no change in aneurysm size, and 2 were performed in patients with a decrease in aneurysm size. Patients with aneurysm enlargement had a mean increase in diameter of 10 Ϯ 6 mm, with a range of 5 to 20 mm before surgical conversion. Patients with enlargement were more likely to undergo surgical conversion (20%) than patients with no change (4%) or decreasing aneurysm size (2%; P Ͻ .0001) (Table V) . However, 80% of patients with aneurysm enlargement have not required surgical conversion. Four of the nine enlargement patients who underwent conversions had been treated with a secondary endovascular procedure before conversion. One patient had emergent conversion following rupture and died in the postoperative period. Elective surgical conversion for enlargement with type II endoleak was performed in eight patients, with two postoperative deaths (25%). Mean aneurysm diameter at the time of elective conversion was 6.8 cm, with a range of 5.4 to 8.0 cm. One patient died after elective conversion at 33 months for enlargement from 5.0 to 6.0 cm with a type II endoleak. The second patient died at 25 months after elective surgical conversion for enlargement from 7.5 to 8.0 with a type II endoleak. Kaplan-Meier estimates for freedom from surgical conversion at 3 years were 81% for patients with aneurysm enlargement, 96% for patients with no change, and 99% for patients with decreasing aneurysm size (log-rank test, P Ͻ .0001) (Table VI) . Rupture. Three of the 383 patients (0.8%) had aneurysm rupture, with one rupture in each of the three patient groups. One patient had aneurysm enlargement of 5 mm at 1 year (6.5-7.0 cm); the aneurysm was 4 mm larger than baseline at 16 months, with a type I iliac fixation endoleak. This patient refused treatment and further follow-up and experienced a rupture at 24 months at a nonstudy site hospital. A CT scan before emergency surgery at the local hospital demonstrated rupture with aneurysm diameter 6 mm larger than core laboratory baseline. One patient with a 6.8-cm aneurysm had no change in aneurysm size and no endoleak at 1 year. There was evidence of insecure proximal fixation in a short angulated neck, however, and the aneurysm ruptured at 14 months. One patient with a 9.0-cm aneurysm had no endoleak and a decrease in aneurysm size to 6.0 cm at 1 year. This aneurysm ruptured at 23 months with evidence of increased angulation of the stent graft, resulting in separation of the iliac junction limb at the time of rupture. Thus all three rupture patients had large aneurysms at baseline (6.5, 6.8, and 9.0 cm) and all three rupture patients died following emergent surgical conversion. Each had been treated with the early "stiff"-body stent graft, which is no longer in use, 24 and each had evidence of insecure stent-graft fixation as the cause of rupture. 13 Kaplan-Meier estimates for freedom from aneurysm rupture at 3 years were 98% for patients with aneurysm enlargement, 99% for patients with no change, and 99% for patients with decreasing aneurysm size (log-rank test, P ϭ 0.8, ns) (Table VI) .
AAA-related death. Five of the 383 patients (1.3%) died of causes related to the aneurysm or stent graft. Three of the five deaths were in patients with aneurysm enlargement: one after emergent conversion for rupture, and two after elective surgical conversion for enlargement with Type II endoleak. One patient with no change in aneurysm size died after surgical conversion for rupture, and one patient with a decrease in aneurysm diameter died after surgical conversion for rupture. Kaplan-Meier estimates for freedom from AAA-related death at 3 years were 93% for patients with aneurysm enlargement, 99% for patients with no change, and 99% for patients with decreasing aneurysm size (log-rank test, P ϭ .005) (Table VI) .
Survival. A total of 55 of the 383 patients (14%) have died. More deaths have occurred in patients with no change in aneurysm size (37 patients, 19%) than in patients with enlarging (6 patients, 13%) or shrinking aneurysms (12 patients, 9%; P ϭ .04). Three of the six deaths in the enlargement group were aneurysm-related, and three were unrelated (two cardiac and one cancer). Kaplan-Meier survival estimates at 3 years were 86% for patients with enlargement, 82% for patients with no change, and 93% for patients with decrease in aneurysm size (log-rank P ϭ 0.02) ( Table VI) .
Predictors of changes in aneurysm size. Analysis of variance revealed the following factors at baseline to be significant predictors of change in aneurysm size following JOURNAL OF VASCULAR SURGERY Volume 39, Number 1 endovascular aneurysm repair: older age (P ϭ .002) and the presence of an endoleak following device implantation (P ϭ .001). Factors that were not predictive of aneurysm enlargement included preoperative aneurysm size, infrarenal neck diameter or length, iliac artery diameter, preoperative patient characteristics and risk factors, stiff-body design, stent-graft migration, and stent-graft patency. Treatment of patients with enlargement. Mean implant duration in the 46 patients with documented aneurysm enlargement was 37 Ϯ 9 months (range, 7-50 months). Twenty of the 46 patients with enlargement (43%) have undergone treatment: 5 patients have undergone elective surgical conversion, 3 patients have undergone surgical conversion after unsuccessful secondary treatment, and 12 patients have undergone successful secondary endovascular treatments. Twenty-six patients (57%) have untreated enlargement, including seven patients with documented aneurysm enlargement of 5 mm or more after a secondary treatment. Three patients with enlargement have died of unrelated causes. Sixteen patients continue to be followed with no secondary treatments, conversions, ruptures, or deaths.
There were no significant differences in age, preoperative, or baseline patient characteristics among treated and untreated patients. There were no differences in preoperative aneurysm size or maximum aneurysm diameter attained during the follow-up period, and no differences in distribution of small and large aneurysms among treated and untreated aneurysms (Table VII ). The endoleak rates were similar between the two groups at 1 year but increased in years 2 and 3 in the treated group and decreased in the untreated group. There was no significant difference in migration rate or duration of follow-up after enlargement was noted. Two patients in the treated group with enlargement and type II endoleaks died following elective surgical conversion. One patient with enlargement who refused treatment of a type I iliac endoleak experienced a rupture and died following emergent conversion. There was no difference in aneurysm-related death rate among treated and untreated patients.
DISCUSSION
Endovascular treatment has been shown to be effective in preventing aneurysm rupture in the great majority of patients; however, aneurysm ruptures have been reported following endovascular repair with all devices. 26, 27 Although it is generally believed that a decrease in aneurysm size along with the absence of an endoleak are reliable indicators of success, 28 the significance of failure of an aneurysm to shrink after endovascular repair is unknown. Numerous investigators have reported on size changes following endovascular repair, with or without endoleaks. [29] [30] [31] [32] [33] [34] [35] [36] [37] However, the true significance of aneurysm size changes with respect to the primary end points of aneurysm repair remains undefined. Indeed, aneurysm ruptures have been reported in patients with decreasing, increasing, and stable aneurysm sizes following endovascular repair, 13, 15, 22 indicating that factors other than aneurysm size changes may be the primary determinants of aneurysm rupture.
In this study we found that 12% of patients experienced aneurysm enlargement following endovascular repair at a mean follow-up time of 3 years. The majority of aneurysms did not change in size, and 36% of aneurysms decreased in size. One patient with aneurysm enlargement of 5 mm, as defined by independent core laboratory measurement, experienced aneurysm rupture, as did one patient with no change in aneurysm size and one patient with a decrease in aneurysm size. We thus could establish no relationship between the risk of rupture and postprocedure aneurysm diameter changes. All three ruptures occurred in patients treated in the beginning of the trial with an early prototype stiff bifurcation module that is no longer used, and each rupture was attributed to a failure of primary device fixation in the aortic neck, iliac artery, or modular device junction. These observations indicate that mechanical factors and issues related to endovascular device fixation may be of importance and complicate this analysis of aneurysm size changes and risk of rupture. This is not to say that size changes are unimportant. Indeed, aneurysm enlargement, particularly if associated with a type I endoleak, may be an important indicator of insecure device fixation that requires immediate treatment. In this study, 43% of patients with enlargement required secondary treatments or surgical conversion. The close and ongoing surveillance of this group of patients along with the high rate of intervention in patients with enlargement may account for the low risk of rupture seen in this study. Similarly, close surveillance and a high rate of intervention was associated with a low risk of aneurysm rupture in prospective, randomized clinical trials of small abdominal aortic aneurysms. 9, 10 During both the United Kingdom small aneurysm trial and the Veterans Affairs Aneurysm Detection and Management Cooperative Study Group trial, more than 60% of the surveillance patients were treated with open surgical repair, thus avoiding potential rupture.
Although we documented aneurysm size (6-mm enlargement) at the time of rupture in only one of the three rupture patients, we cannot exclude the possibility that significant enlargement may have occurred in the other two rupture patients at some time after the last CT scan evaluated by the core laboratory and before rupture. However, our data indicate that patients with documented enlargement during surveillance following endovascular repair do not seem to be at increased risk of rupture on this basis alone. Similarly, patients with shrinking aneurysms noted during surveillance do not seem to be protected from rupture on this basis alone. Wolf 38 has suggested that true "regression" with protection from rupture does not occur and that sudden re-exposure of the shrunken aneurysm to pulsatile aortic flow, such as can occur if there is loss of fixation or graft integrity, could cause sudden re-expansion of the aneurysm and rupture. This may have been the case in the patient in this study who experienced a rupture despite a 3-cm decrease in aneurysm size. If it is assumed that this 6-cm "shrunken" aneurysm re-expanded to its original size of 9 cm when the iliac limb became disconnected, then the mean aneurysm size at the time of rupture in the three rupture patients would be 7.8 cm. If the core laboratory size of 6 cm is used for the size at the time of rupture, then mean aneurysm size for the three ruptures would be 6.8 cm. In any case, only large aneurysms ruptured in this experience, consistent with the well-known relationship between aneurysm size and risk of rupture. There were no ruptures in aneurysms Ͻ6 cm in diameter, Aneurysm-related death is a primary long-term end point of both open and endovascular aneurysm repair. 28, 39 Aneurysm-related death is defined as any death that occurs within 30 days of the primary aneurysm treatment or within 30 days of any secondary treatment (or within the primary hospitalization if longer), or any death related to the aneurysm or graft or a surgical conversion at any time. 28 In this analysis, we included all patients treated during the AneuRx Phase II trial who had core laboratory evaluation of aneurysm size change, and we found five aneurysm-related deaths among 383 patients. However, we excluded from our patient cohort seven patients in the Phase II trial who died within 30 days of the primary endovascular procedure because core laboratory analysis of aneurysm size change was not available in these patients. Had these seven aneurysm-related deaths been included, the aneurysm-related deaths for the entire Phase II and emergency use population of 470 patients would be 98% at 1 year, 97.7% at 2 years, and 97.1% at 3 years, with 297 patients at risk at 3 years. This is similar to the aneurysm-related death rate for the entire AneuRx patient cohort of 1193 patients treated during Phases I, II, and III, including emergency-use patients, 25, 40 and is lower than the calculated aneurysmrelated death rates following open surgical repair. 39, [41] [42] [43] The aneurysm-related death rate for patients with enlargement included two deaths in patients with type II endoleak enlargement of 5 to 6 cm and 7.5 to 8 cm and endoleak who underwent elective surgical conversion. The mortality rate for elective surgical conversion in enlargement patients in this experience was 2 of 8 (25%), and this must be taken into consideration when evaluating the risk of surgical conversion versus continued observation of enlarging aneurysms in individual patients, particularly those with small aneurysms.
The group of 46 patients with enlargement included 26 patients who were followed up with no treatment for an average time of 23 months following documentation of enlargement. There were no significant differences in enlarged aneurysm size (6.4 cm), maximum amount of enlargement, or duration of follow-up among untreated and treated patients. The most remarkable difference was that untreated patients had a declining endoleak rate from 47% at 1 year to 25% at 3 years, whereas the treated group had an increasing endoleak rate from 65% at 1 year to 100% at 3 years. There were two deaths in the treated group related to elective surgical conversion and one death in the untreated group related to rupture, highlighting the importance of careful follow-up and clinical judgment in following up this group of patients. The 1-year expected risk of rupture in untreated 6.4-cm aneurysms is 10%. 6 We observed one rupture among 26 untreated patients (4%) over a 3-year period, and this patient refused recommended treatment of a type I endoleak. This indicates that continued observation of some patients with aneurysm enlargement following endovascular repair is a viable clinical option.
In this analysis we have included all patients treated during Phase II in an intent-to-treat analysis. This includes 46 emergency-use patients who did not meet the inclusion criteria for the Phase II study for a variety of reasons, including not meeting the morphologic requirements of a neck of at least 1 cm in length and iliac arteries Ͻ15 mm. Thirty-two of these patients had core laboratory data and are included in this report. The inclusion of these patients did not influence the final results, and there were no differences in adverse events rates in these patients. Three of the 46 patients who enlarged were emergency-use patients, and none had ruptures or surgical conversion. There were no aneurysm-related deaths in these patients.
Endoleaks are strongly associated with aneurysm enlargement. 26, 33, 36 In this study there was evidence of endoleak at some time during the follow-up in most patients with enlargement. Although 38% of patients with shrinking aneurysms also had documentation of endoleak at some time following device implantation, only 2% had ongoing endoleaks at 1 year. In contrast, 55% of enlargement patients had endoleaks at 1 year. However, most patients (83%) with documented endoleak following endovascular repair did not experience aneurysm enlargement and had stable or decreasing aneurysm size. Only 17% of patients with endoleak had evidence of aneurysm enlargement during the course of the follow-up period. Furthermore, endoleak does not seem to be a significant predictor of primary outcome measures after endovascular repair 23 particularly rupture. In this study two of the three patients who had ruptures had no endoleak on core laboratory analysis. This, however, does not rule out the possibility that a new endoleak might have developed in these two patients between the time of the last core laboratory evaluation and the subsequent rupture. Although it is often assumed that endoleak, or endotension, is the predisposing cause of rupture, other factors, such as intrinsic patientrelated biologic factors and aneurysm wall matrix metalloproteinase activity, may play larger roles in determining aneurysm size changes and risk of rupture. Whereas the causes of aneurysm enlargement remain unclear, it seems that continued blood flow in the aneurysm sac, such as exists with presence of a type I or a type II endoleak may be required to facilitate aneurysm enlargement, even though it may not have a causal relationship. 32, 34, 36, 44 It is interesting to note that the factors that were not associated with enlargement following endovascular repair included hypertension, smoking, and chronic obstructive pulmonary disease, which have been identified as factors related to enlargement of untreated aneurysms. 42 Although the majority of aneurysms in this study did not change in size (52%), the rate in change of enlarging and shrinking aneurysms was the same (0.31 mm/mo) in this study. This finding has previously been noted by Wolf 38 and is similar to the annual rate of enlargement of 0.36 mm/mo reported from the VA prospective surveillance study of untreated aneurysms. 6 Others have reported similar rates of enlargement of untreated aneurysms, ranging from 2.6 to 6.6 mm/y. 8, 29, 44, 45 However, enlargement rate is not linear, and there is great variability and unpredictability in enlargement rates of individual aneurysms. 46 In clinical practice, significant aneurysm enlargement following endovascular repair is a cause for concern, particularly when it is associated with type I endoleaks. 26 Thus it is not surprising that the rate of secondary procedures and surgical conversions was significantly higher in the enlargement group. At a mean follow-up of 3 years, 20% of patients had been converted to open surgical repair. However, it is notable that 80% of patients have not required open surgical repair, and 57% of patients have not required any additional treatment, despite aneurysm enlargement. Of those who have required further intervention, the majority have undergone endovascular treatment. The risk of rupture appears to more likely be caused by aortic aneurysm size rather than to the presence of 5 mm or more of enlargement. Thus, careful clinical follow-up with serial imaging and appropriate treatment as clinically indicated appear to be successful in avoiding rupture in the vast majority of patients. Indeed, rupture appears to be related primarily to aneurysm size and to the security of stent-graft fixation, rather than to the presence of endoleak or changes in aneurysm size. 13, 24 
CONCLUSION
Aneurysm enlargement of 5 mm or more occurs in 12% of patients following endovascular repair with the AneuRx stent graft. In our series, enlargement is associated with increasing age and the presence of a persisting endoleak. Patients with aneurysm enlargement are more likely to undergo a secondary endovascular procedure or conversion to open surgical repair than those without enlargement and are at increased risk of aneurysm-related death. Patients with enlargement do not appear to be at increased risk of aneurysm rupture or decreased survival at a mean follow-up time or at 3 years. Aneurysm size rather than aneurysm enlargement may be a more important indicator of rupture risk. However, longer follow-up is required to ascertain the true long-term significance of aneurysm size changes following endovascular repair.
